Prevalence of iron deficiency in patients admitted to a geriatric unit: a multicenter cross-sectional study

期刊论文
出版模式：

开放获取
发表日期：

2024年1月30日

查看全文

Bertrand Fougère,
François Puisieux,
Pascal Chevalet,
Cédric Annweiler,
Emeline Michel,
Laure Joly,
Frédéric Blanc,
Abdelghani EL Azouzi,
Valérie Desré-Follet,
Patrice Cacoub,
Anne-Sophie Billet,
Florent Fiasson,
Antoine Garnier-Crussard,
Isabelle Goidin,
Marc Paccalin,
Laure Parnet,
Mikel Sarasibar,
Caroline Thomas

摘要

Background

Iron deficiency (ID) is often associated with other comorbidities in older patients and is a factor of morbimortality. However, the prevalence of ID remains poorly documented in this population.

Methods

The CARENFER PA study was a French multicenter cross-sectional study whose objective was to evaluate ID in patients (> 75 years) admitted to a geriatric unit. The primary endpoint was the ID prevalence defined as: serum ferritin < 100 µg/L and/or transferrin saturation coefficient (TSAT) < 20%. The Short Physical Performance Battery (SPPB) test was used to identify older patients at high risk of adverse events (e.g., disability, falls, hospitalization, death).

Results

A total of 888 patients (mean age, 85.2 years; women, 63.5%) from 16 French centers were included from October 2022 to December 2022. The prevalence of ID was 57.6% (95% CI, 54.3–60.9) in the cohort of older patients (62.6% in anemic and 53.3% in non-anemic patients; p = 0.0062). ID prevalence increased significantly with the presence of more than three comorbidities (65.6% vs. 55.9%; p = 0.0274), CRP ≥ 12 mg/L (73.0% vs. 49.3%; p < 0.001) and treatment that may influence ID/anemia (60.5% vs. 49.6%; p = 0.0042). In multivariate analysis, only CRP ≥ 12 mg/L was an independent predictive factor of ID (odds ratio, 2.78; 95% CI, 1.92–4.08; p < 0.001). SPPB scores were low (0–6) in 60.5% of patients with ID versus 48.6% of patients without ID (p = 0.0076).

Conclusion

More than half of older patients had ID, including non-anemic patients. ID was associated with the presence of inflammation and a low SPPB score.

Trial registration

NCT05514951.